Press release
Digitized versions of medical charts to flood the Pulmonary Fibrosis Treatment Market at a CAGR of 6.2%
Pulmonary Fibrosis Treatment Market 2022Healthcare therapies are bound to witness renaissance in the years to come with technologies like Artificial Intelligence making inroads. "Augmented Intelligence" is the key concept used to serve assistive purposes. However, this certainly does not mean that it would replace clinicians. It would, instead, mean that it would improvise on the efforts of clinicians. Personalized healthcare is slated to be another important aspect of healthcare therapies in the forecast period. This would be the scene with healthcare therapies market in the near future.
Monotherapy is cost-effective and gives deliverable action directly to the site of action in a few minutes, and is said to be a safe and effective method for treating idiopathic pulmonary fibrosis (IPF). According to Persistence Market Research (PMR), request for pulmonary fibrosis treatment is predicted to increase, enabling the market to surpass US$ 2.7 Bn by 2021. Over the coming years, rising cases of IPF will support the expansion of the market.
Get Free Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/30070
Incidence of IPF is rising and the disease is estimated to affect 3 million people globally (13 to 20 per 100,000 people). Considering the current pandemic scenario, global burden of fibrotic lung disease is expected to rise largely as a result of SARS-CoV-2/COVID-19. This can be primarily attributed to long-term exposure of patients to mechanical ventilation. 81% patients are aged more than 40 years with pulmonary fibrosis, as per the Pulmonary Fibrosis Foundation.
High number of research & development projects, increasing investments, and favorable regulatory policies are some other factors supporting growth of the market for pulmonary fibrosis treatment. Majority of the population living with pulmonary fibrosis is being treated with traditional corticosteroid combination drugs with limited efficacy. With the arrival of new novel therapies, unaddressed populations in middle- and lower-income countries, as well as developed countries, can offer significant revenue generation opportunities.
Key Take aways from Market Study
The global pulmonary fibrosis treatment market is expected to rise at a healthy CAGR over more than 6% through 2031.
Increasing focus on effective treatment in the U.S is lending high Y-o-Y growth to the market in the country.
Germany and France are expected to exhibit increasing demand to tackle concerns pertaining to rising incidence of IPF.
Overall, the global market is set to expand 2X over the next ten years.
Monotherapy to account for over 70% market share by 2031.
Get To Touch in our Expert @ https://www.persistencemarketresearch.com/ask-an-expert/30070
"Rising prevalence of idiopathic pulmonary fibrosis and importance of early diagnosis are creating growth opportunities for market players in the long term," says a Persistence Market Research analyst.
Collaborations and Product Approval - Imperative Strategy for Market Players
Leading market players are strengthening their market position through collaborations with various other organizations.Global leading companies are focusing on research activities and approvals for increased market penetration.
Roche, in March 2020, received Breakthrough Therapy Designation (BTD) from the U.S FDA for Esbriet (pirfenidone), for use in adults with unclassifiable interstitial lung disease (uILD).
In June 2019, Boehringer Ingelheim entered into a collaboration andlicense agreement with Bridge Biotherapeutics Inc. (South Korea), with the aim to fast-track the development of Bridge's autotaxin inhibitor BBT-877 for treatment against fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis, a rare lung disease.
In October 2020, Cipla introduced the generic version Nintedanib for the treatment of idiopathic pulmonary fibrosis. In India, this drug will be marketed under the brand name Ninitb. Nintedanib will be available in two formulations of 100 mg and 150 mg.
What else is in the report?
Persistence Market Research offers a unique perspective and actionable insights on the pulmonary fibrosis treatment market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031, based on therapy (monotherapy, combination therapy and symptomatic treatment), indication (idiopathic pulmonary fibrosis (IPF), familial PF, and others), and distribution channel (hospital pharmacies, retail pharmacies, and mail order pharmacies), across seven key regions of the world.
Key geographies evaluated in this report are:
North America - U.S, Canada
Europe - France, Germany, Italy, Spain, and the UK, Eastern Europe, CIS
APAC - China, India, Japan, Australia, Others
Latin America - Argentina, Brazil, Others
Access Full Report @ https://www.persistencemarketresearch.com/checkout/30070
Key Questions Answered in This Report.
What will the Market growth rate in Future?
What are the key factors driving the global Market?
Who are the key manufacturers in Market space?
What are the opportunities and threats faced by the vendors in the global industry?
What are sales, revenue, and price analysis by regions of industry?
Contact us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Digitized versions of medical charts to flood the Pulmonary Fibrosis Treatment Market at a CAGR of 6.2% here
News-ID: 2798499 • Views: …
More Releases from Persistence Market Research

Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health …
Overview of the Global Fruit Ingredients Market
The global fruit ingredients market is witnessing significant growth, driven by rising consumer demand for natural, clean-label, and nutrient-rich food products. In 2025, the market is likely to be valued at US$ 75.0 billion and is expected to reach US$ 111.3 billion by 2032, registering a robust CAGR of 5.8% during the forecast period. Fruit ingredients, which include fruit concentrates, purees, powders, and extracts,…

Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Pla …
Overview of the Market
The global vegan dessert market is poised for significant expansion, with an estimated valuation of US$ 5.2 billion in 2025, projected to reach US$ 11.9 billion by 2032. This robust growth reflects a compound annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2032. Increasing consumer awareness about health, environmental sustainability, and ethical food consumption is driving the widespread adoption of vegan dessert…

Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenienc …
Overview of the Global Instant Beverage Premix Market
The global instant beverage premix market has witnessed remarkable growth over the past decade, driven by evolving consumer lifestyles and increasing demand for convenient, ready-to-consume beverages. Instant beverage premixes, encompassing products such as instant coffee, tea, flavored drinks, protein powders, and nutritional supplements, cater to busy consumers seeking quick preparation without compromising on taste or nutritional value. These premixes have gained popularity across…

Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Mar …
The global dermacosmetics market, estimated at US$ 53 billion in 2025, is forecasted to witness a steady upward trajectory, expanding at a Compound Annual Growth Rate (CAGR) of 7.4% to reach US$ 87.3 billion by 2032. This surge is driven by a confluence of factors ranging from increasing consumer awareness and the rising incidence of skin conditions to a growing preference for advanced, dermatologist-backed skincare solutions. Dermacosmetics, a category that…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…